Impact of dose and administration schedule on biologic efficacy in chronic rhinosinusitis with nasal polyps: a network meta-analysis.

What was studied

This study looked at adults with long-term sinus swelling and nasal polyps. The team pooled data from earlier trials. In each trial, people were put into groups by chance. The drugs act on a kind of swelling called type 2 inflammation. They were dupilumab, omalizumab, mepolizumab and benralizumab. Each drug was tested against a dummy drug. The team asked how the dose, and how often it was given, changed results.

What they found

The review took in trials with 4,861 patients in all. Dupilumab ranked first for quality of life. Here it was 600 mg to start, then 300 mg every 1-2 weeks. Dupilumab also gave the largest gain in sense of smell. Benralizumab 30 mg every 4 weeks ranked first for shrinking polyps. Results on quality of life and polyp size varied a lot between trials. Results on smell were much more steady across trials.

What it means for patients

The authors say each drug's effect depends on the goal and the dose plan. Dupilumab seemed to do the most for daily life and smell. Benralizumab given every 4 weeks seemed to shrink polyps the most. The authors say the choice of drug should fit each patient's traits and goals.

Why it is not certain yet

Trial results on quality of life and polyp size were quite mixed. In those parts, the data did not agree well across the whole set. So those rankings are less sure. The trials took in only adults. A review can only be as good as the trials in it.

Source

Impact of dose and administration schedule on biologic efficacy in chronic rhinosinusitis with nasal polyps: a network meta-analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.